Shop by goal

Popular compounds

GHK-Cu

Retatrutide

Research resources

Certificates of Analysis

Retatrutide: Metabolic / Fat Loss research guide

In short: Retatrutide, research triple agonist of the GLP-1 / GIP / glucagon receptor system — among the largest body-composition changes reported in incretin-class research. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use, not for human or clinical use.

Not medical advice. Retatrutide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.

Retatrutide at a glance

Compound type

Research peptide

Research category

Metabolic / Fat Loss

Also known as

GGG Triple Agonist, GLP-1/GIP/Glucagon Receptor Triple Agonist, Tri-Agonist

Molecular weight

4,894.6 Da

Research-grade purity

>99% HPLC

Evidence context

Preclinical / research use only

Regulatory status

Not an approved medicine. Supplied as a research compound

Last reviewed

23 July 2026

What to know first

First-in-class triple GLP-1/GIP/GCGR agonist, most comprehensive incretin receptor coverage in development

Phase 3 TRIUMPH-1: 28.3% mean weight reduction at 80 weeks with the 12 mg dose; 45.3% achieved ≥30% reduction

Glucagon receptor activation drives hepatic thermogenesis and energy expenditure beyond appetite suppression

GIPR potency 8.9-fold greater than native GIP enhancing satiety and metabolic signaling

Details and limits sit in the sections below. Research use only.

What Retatrutide is

Retatrutide is a triple receptor agonist of the GLP-1 / GIP / glucagon system, with the largest body-composition effects reported for any incretin-class peptide in published research.

One-paragraph overview from our research datasheet. Still scientific, but faster to read than the full mechanism list below.

Retatrutide, research triple agonist of the GLP-1 / GIP / glucagon receptor system — among the largest body-composition changes reported in incretin-class research.

Research contexts

Peer-reviewed papers discuss Retatrutide in specific lab settings. The points below reflect research questions, not health claims.

Research vs. personal use: Literature describes experiments in cells and animals. That is distinct from real-world use. Our products are for laboratory research only.

Typical study contexts

Incretin pathways, food intake and glucose handling in rodent models.

Some drug-class molecules have clinical trials. Those are distinct from catalogue research use.

First-in-class triple GLP-1/GIP/GCGR agonist, most comprehensive incretin receptor coverage in development.

Phase 3 TRIUMPH-1: 28.3% mean weight reduction at 80 weeks with the 12 mg dose; 45.3% achieved ≥30% reduction.

Glucagon receptor activation drives hepatic thermogenesis and energy expenditure beyond appetite suppression.

GIPR potency 8.9-fold greater than native GIP enhancing satiety and metabolic signaling.

Why Metabolic / Fat Loss research matters

Metabolic peptides are studied for appetite signals, incretin pathways and energy balance. Literature emphasises mechanisms, not lifestyle advice.

Mechanisms (technical review)

Our datasheet lists mechanistic themes from preclinical work. These are research endpoints, not health claims.

First-in-class triple GLP-1/GIP/GCGR agonist, most comprehensive incretin receptor coverage in development

Phase 3 TRIUMPH-1: 28.3% mean weight reduction at 80 weeks with the 12 mg dose; 45.3% achieved ≥30% reduction

Glucagon receptor activation drives hepatic thermogenesis and energy expenditure beyond appetite suppression

GIPR potency 8.9-fold greater than native GIP enhancing satiety and metabolic signaling

Liver fat reduction up to 82.4% in MASLD, superior to dual agonist approaches

Phase 2 (NEJM 2023): 24.2% mean weight reduction at 48 weeks — the largest single-molecule effect then reported in the incretin class

Lab handling & preparation

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation.. See the storage guide.

Research dosing context: Literature typically discusses 1–12 mg subcutaneously (dose escalation protocol). Once weekly subcutaneous injection Dose-proportional PK; t½ ≈ 6 days; Tmax = 12–72 h; hepatic metabolism without CYP interaction; dose escalation: 1 mg → 2 mg → 4 mg → 8 mg → 12 mg over 20–24 weeks in clinical protocols. Phase 3 TRIUMPH-1 (obesity) reported in 2025; further TRIUMPH readouts (type 2 diabetes, cardiovascular/kidney outcomes) expected through 2026.

Preparation: Follow the reconstitution guide. Confirm volumes with the calculator.

Purity check: Use the COA reading guide and the published Retatrutide Certificate of Analysis.

Common Questions People Are Asking

What is retatrutide?

Retatrutide is an investigational triple agonist — it activates the GLP-1, GIP and glucagon receptors — developed by Eli Lilly and still in clinical trials (not approved anywhere). Retatrutide is the research-grade form of this retatrutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is not an approved medicine and is not for human use.

What does retatrutide do?

In published research retatrutide activates three receptors at once — GLP-1 and GIP (satiety, insulin secretion, adipose effects) plus glucagon (hepatic energy expenditure and liver-fat clearance). The triple mechanism is what distinguishes it from dual (tirzepatide) and single (semaglutide) agonists. These are research findings for the molecule, not human-use guidance; Retatrutide is supplied for research only.

Is retatrutide FDA approved?

No. Retatrutide is still in clinical trials and is not approved by the FDA, EMA, or any other regulator. Retatrutide is an unapproved, research-grade lyophilised powder supplied for laboratory research use only — not for human consumption.

Is retatrutide safe?

Retatrutide is investigational; its safety is still being characterised in clinical trials and is not established for general use. Research-grade Retatrutide is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.

How much bacteriostatic water do you mix with 10 mg of retatrutide, and how is it reconstituted?

For laboratory preparation, concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added — e.g. a 10 mg vial reconstituted with 1 mL of bacteriostatic water gives 10 mg/mL, or with 2 mL gives 5 mg/mL. Keep the reconstituted vial refrigerated at 1–6 °C and protected from light. This is preparation math only; New-U provides no human-use dosing guidance.

How is Retatrutide different from Tirzepatide or Semaglutide?

Semaglutide targets one receptor (GLP-1), Tirzepatide targets two (GLP-1 and GIP), and Retatrutide targets three (GLP-1, GIP, and glucagon). The glucagon arm is what drives the additional hepatic thermogenesis and liver-fat clearance that set Retatrutide apart in published research.

Why is the glucagon receptor useful here? Glucagon raises blood sugar, right?

It does, but at the right intensity and in combination with GLP-1, glucagon receptor agonism stimulates hepatic energy expenditure and fat oxidation without significant net glucose elevation. The GLP-1 arm offsets any glycemic downside while the glucagon arm delivers unique energy-balance effects.

Is Retatrutide an approved medicine?

No. Retatrutide is supplied for in-vitro and preclinical research only and is not approved as a medicine in any jurisdiction.

How is Retatrutide research-supply duration calculated?

Supply duration is a mathematical estimate: divide the total milligrams in your selected vial or sealed pack by a published weekly study amount from the clinical literature. For example, one 10 mg vial at 2 mg per week equals about 5 weeks of material (10 ÷ 2 = 5). A sealed 10-vial pack of 10 mg vials (100 mg total) at the same schedule equals about 50 weeks (100 ÷ 2 = 50). This is material arithmetic only — it does not recommend a protocol, establish reconstituted stability, or imply human-use guidance. Retatrutide is supplied for laboratory research only.

What is the typical research dose escalation?

Published research protocols use a step-up schedule from 1 mg weekly, doubling over several weeks to 2 mg, 4 mg, 8 mg, and ultimately 12 mg. The gradual escalation is designed to minimise GI signals as systems adapt to triple-receptor activation.

Retatrutide vs tirzepatide — which showed more weight loss in research?

In their respective obesity programmes the triple agonist reported larger mean reductions: retatrutide reached about 24.2% at 48 weeks in Phase 2 (NEJM 2023) and 28.3% at 80 weeks in Phase 3 TRIUMPH-1, while tirzepatide reported about 20.9% at 72 weeks in SURMOUNT-1. The difference is widely attributed to retatrutide's added glucagon-receptor arm, which raises energy expenditure on top of appetite suppression. These are cross-trial descriptive comparisons, not head-to-head results, and both compounds are supplied only as research-grade material for laboratory use, not for human use.

How is retatrutide reconstituted and stored?

Keep the lyophilised powder at −20 °C in the freezer. Reconstitute with bacteriostatic water directed down the vial wall and swirl gently rather than shaking; the in-solution concentration in mg/mL equals the vial mass divided by the millilitres of diluent added. Refrigerate the reconstituted vial at 1–6 °C, protect it from light, and avoid repeated freeze-thaw cycles, which can damage the C20 fatty-acid tail. This is laboratory-handling guidance only — not a human-use protocol.

What happens when you stop taking GLP-1s?

Across the published GLP-1 literature, withdrawal of a GLP-1 receptor agonist is consistently followed by the return of appetite and partial-to-substantial regain of lost weight, because the appetite and gastric-emptying effects depend on continued receptor activation. Retatrutide is a triple GIP/GLP-1/glucagon agonist still in clinical trials, so any such observations describe investigational or approved medicines in human studies. Retatrutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.

Is this page medical advice? Can I use Retatrutide for my health?

No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

Where do I find Retatrutide specs, purity certificates and pricing?

Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.

Related peptide guides

Other compounds researchers often read about alongside Retatrutide.

Semaglutide - companion guide

Tirzepatide - companion guide

Cagrilintide - companion guide

Eloralintide - companion guide

Scientific sources & further reading

Primary literature and registries for Retatrutide, plus mainstream coverage of the peptide category. Research use only - not medical advice.

Databases & literature:

PubMed: peer-reviewed literature on Retatrutide

ClinicalTrials.gov: registered studies on Retatrutide

Retatrutide: Wikipedia (search)

Peptides in the news:

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Ready to order? View full product specs

Access concentration, batch info, variants, and current pricing on our shop.

Also known as: GGG Triple Agonist, GLP-1/GIP/Glucagon Receptor Triple Agonist, Tri-Agonist

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics. Published Certificates of Analysis for released sale batches. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.